David Bachelder - Oct 1, 2024 Form 3 Insider Report for Quipt Home Medical Corp. (QIPT)

Role
Exec VP Operations
Signature
/s/ David Bachelder
Stock symbol
QIPT
Transactions as of
Oct 1, 2024
Transactions value $
$0
Form type
3
Date filed
10/1/2024, 08:11 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding QIPT Common Shares 2.16K Oct 1, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding QIPT Stock Option (right to buy) Oct 1, 2024 Common Shares 50K $4.99 Direct F1
holding QIPT Stock Option (right to buy) Oct 1, 2024 Common Shares 30K $6.14 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price for this award is denominated in Canadian dollars at 6.75. Options to purchase 41,666 Common Shares have vested according to the award agreement and are, as of October 1, 2024, exercisable. Options to purchase 4,166 Common Shares will vest on November 2, 2024, and options to purchase 4,167 Common Shares will vest on February 2, 2025. Converted from Canadian dollars to United States dollars as of the date hereof at a conversion rate of 0.74 United States dollars per Canadian dollar.
F2 The exercise price for this award is denominated in Canadian dollars at 8.30. Options to purchase 15,000 Common Shares have vested according to the award agreement and are, as of October 1, 2024, exercisable. Options to purchase 2,500 Common Shares will vest on each of November 20, 2024, February 20, 2025, May 20, 2025, August 20, 2025, November 20, 2025, and February 20, 2026. Converted from Canadian dollars to United States dollars as of the date hereof at a conversion rate of 0.74 United States dollars per Canadian dollar.

Remarks:

Quipt Home Medical Corp. (the "Issuer") has determined that it ceased to be a "foreign private issuer" as of March 31, 2024. As a result, effective October 1, 2024, the Issuer is required to comply with the reporting requirements and use the filing forms applicable to U.S. public companies under U.S. securities laws, including reports required under Section 16 of the U.S. Securities Exchange Act of 1934.